XML 37 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration and Other Agreements, Roche (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
performance_obligation
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
performance_obligation
Collaboration and Other Agreements [Line Items]                          
Revenues     $ 25,192,000 $ 18,741,000 $ 10,593,000 $ 9,662,000 $ 15,794,000 $ 20,798,000 $ 18,834,000 $ 4,695,000 $ 64,188,000 $ 60,121,000 $ 157,742,000
Deferred revenue   $ 27,318,000         40,722,000         40,722,000 $ 27,318,000
Deferred revenue, current     10,700,000       21,721,000       10,700,000 21,721,000  
Deferred revenue included in long-term liabilities     9,153,000       19,001,000       9,153,000 19,001,000  
Roche                          
Collaboration and Other Agreements [Line Items]                          
Non-refundable upfront payment $ 10,000,000.0                        
Potential milestone payments and royalties on future sales     370,000,000.0               370,000,000.0    
Number of performance obligations | performance_obligation   1                     1
Transaction price   $ 10,000,000.0                     $ 10,000,000.0
Expected period of development   30 months                      
Revenues                     6,000,000.0 4,000,000.0  
Deferred revenue     $ 0               $ 0    
Deferred revenue             6,000,000.0         6,000,000.0  
Deferred revenue, current             4,000,000.0         4,000,000.0  
Deferred revenue included in long-term liabilities             $ 2,000,000.0         $ 2,000,000.0